← All trials
NCT05878288
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2023
- Primary completion
- May 31, 2029
- Completion date
- May 31, 2029
- First posted
- May 26, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peter MacCallum Cancer CentreLead sponsor
- RegeneronCollaborator
- SanofiCollaborator
- Monash UniversityCollaborator
- University of MelbourneCollaborator
- University of AdelaideCollaborator
- Peter MacCallum Cancer CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.